bluebird bio Stock (NASDAQ:BLUE)
Previous Close
$0.47
52W Range
$0.45 - $5.53
50D Avg
$0.53
200D Avg
$0.95
Market Cap
$89.78M
Avg Vol (3M)
$7.38M
Beta
0.80
Div Yield
-
BLUE Company Profile
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
BLUE Performance
Peer Comparison
Ticker | Company |
---|---|
YMAB | Y-mAbs Therapeutics, Inc. |
PTCT | PTC Therapeutics, Inc. |
ZNTL | Zentalis Pharmaceuticals, Inc. |
CVAC | CureVac N.V. |
SRPT | Sarepta Therapeutics, Inc. |
TVTX | Travere Therapeutics, Inc. |
KPTI | Karyopharm Therapeutics Inc. |
VIR | Vir Biotechnology, Inc. |
VKTX | Viking Therapeutics, Inc. |
AGIO | Agios Pharmaceuticals, Inc. |
KRYS | Krystal Biotech, Inc. |
MRSN | Mersana Therapeutics, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |